Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q3 EPS Loss of $0.10

Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $584 thousand versus the consensus estimate of $500 thousand.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
• Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Morgan Stanley
• Dollar Tree (DLTR) Tops Q2 EPS by $1.59, Beats on Revenue; Offers FY Guidance